Interlaced Chemotherapy For Recurrent High-Grade Gliomas

Many conventional cytotoxic chemotherapies exert their effects during the S or M phase of the cell cycle. One of the major drawbacks of these drugs is that the number of tumor cells destroyed is limited to those cells that happen to be in S or M phase during the treatment.

In Interlaced Therapy, a T-type calcium channel blocker is administered to arrest cancer cells at the G1/S checkpoint of the cell cycle. Then, administration of the T-type calcium channel blocker is stopped and administration of chemotherapy begins. Since the T-type calcium channel blocker increases the number of cancer cells entering S phase at the same time, the number of cancer cells susceptible to the toxic effect of the S phase cytotoxin is greatly increased.

By synchronizing the cell cycle first and then withdrawing it and administering a cytotoxic drug, tumor cell destruction increases without increasing patient exposure to chemotherapy.

I like this approach because it results in magnifying the effects of conventional cancer chemotherapies on cancer cells, greatly increasing the efficacy of current chemotherapies and helping to overcome resistance to them while having no adverse effect on healthy cells.

The following is a link to an Interlaced Therapy clinical trial for patients with high-grade glioma, glioblastoma, anaplastic astrocytoma, anaplastic oligodendroglioma, mixed anaplastic oligoastrocytoma and anaplastic ependymoma that has recurred after standard radiation therapy/temozolomide (TMZ).

Tau Therapeutics LLC joins National Cancer Institute to Study Interlaced Therapy In Patients with Recurrent High-Grade Glioma.

Speak Your Mind